A retrospective observational cohort study assessing ALK inhibitor sequencing and outcomes among ALK-Positive (ALK+) NSCLC patients in the US Community Oncology Setting
Latest Information Update: 17 Oct 2019
At a glance
- Drugs Alectinib (Primary) ; Brigatinib (Primary) ; Ceritinib (Primary) ; Crizotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 17 Oct 2019 New trial record
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer